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Abstract:  Tobacco  smoke  is  a  toxic  and  carcinogenic  mixture  of  more  than  5,000 
chemicals. The present article provides a list of 98 hazardous smoke components, based on 
an  extensive  literature  search  for  known  smoke  components  and  their  human  health 
inhalation risks. An electronic database of smoke components containing more than 2,200 
entries was generated. Emission levels in mainstream smoke have been found for 542 of 
the components and a human inhalation risk value for 98 components. As components with 
potential carcinogenic, cardiovascular and respiratory effects have been included, the three 
major smoke-related causes of death are all covered by the list. Given that the currently 
used Hoffmann list of hazardous smoke components is based on data from the 1990s and 
only  includes  carcinogens,  it  is  recommended  that  the  current  list  of  98  hazardous 
components  is  used  for  regulatory  purposes  instead.  To  enable  risk  assessment  of 
components  not  covered  by  this  list,  thresholds  of  toxicological  concern  (TTC)  have  
been established from the inhalation risk values found: 0.0018 µ g day
−1 for all risks, and 
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1.2 µ g day
−1 for all risks excluding carcinogenicity, the latter being similar to previously 
reported inhalation TTCs.  
Keywords:  smoke  component;  risk  assessment;  tobacco  product  regulation;  Hoffmann  
list; TTC 
 
1. Introduction  
Tobacco  smoke  is  a  complex,  dynamic  and  reactive  mixture  containing  an  estimated  5,000 
chemicals [1-3]. This toxic and carcinogenic mixture is probably the most significant source of toxic 
chemical exposure and chemically mediated disease in humans [4,5]. According to WHO estimates, 
5.4 million premature deaths  are  attributable  to  tobacco  smoking  worldwide  [6]. If current trends 
continue, 10 million smokers per year are anticipated to die by 2025 [7,8]. The most common tobacco 
smoke related causes of death are cardiovascular disease, chronic obstructive pulmonary disease, and 
various types of cancer, in particular lung cancer [9]. In addition, environmental tobacco smoke also 
significantly increases the risk to develop these and other diseases [10]. Obviously, there is a need for 
regulation of this addictive and harmful product as are most other addictive and/or hazardous products 
to which the population is exposed. Nevertheless, as yet tobacco products are only loosely regulated 
and largely exempt from any safety standards.  
The  WHO  Framework  Convention  on  Tobacco  Control  (FCTC)  provides  a  comprehensive 
framework  for  global  tobacco  control  efforts.  The  FCTC  covers  all  aspects  of  tobacco  control, 
including tobacco product regulation, advertising, health warnings, price and tax issues, illicit trade 
(smuggling) and programs for smoking cessation. Article 9 of FCTC addresses the regulation of the 
contents  of  tobacco  products,  including  their  emissions.  The  implementation  of  article  9  requires 
product regulation measures based on the empirical testing of tobacco products using standardized 
methods. It is not feasible to measure all 5,000 cigarette smoke components for product monitoring 
and subsequent regulation purposes. Therefore, a list of smoke components needs to be selected with a 
sufficiently broad chemical, toxicological, and pharmacological profile.  
Currently,  both  the  tobacco  industry  and  authorities  strongly  focus  on  the  so-called  Hoffmann 
analytes.  Hoffmann  and  his  co-workers  have  published  several  lists  with  varying  numbers  of 
biologically or toxicologically active mainstream smoke components, which are colloquially referred 
to as Hoffmann analytes [1,11,12]. The list of Hoffmann analytes is, however, not state-of-the art, as it 
is based on research from the early 1990s. Furthermore, the Hoffmann publications give no arguments 
for  inclusion  of  the  listed  components  apart  from  general  statements  that  these  components  are 
biologically active components in mainstream smoke, or that they are carcinogens or major tobacco 
smoke components. Finally, no endpoints other than carcinogenicity are specified, whereas cancer is 
only one of three major tobacco-related diseases. Other toxicological endpoints such as those related to 
cardiovascular and pulmonary disease need to be included as well. 
For  these  reasons  we  propose  that  the  Hoffmann  list  needed  to  be  revised.  The  present  paper 
describes the development of an up-to-date list of hazardous tobacco smoke components together with 
inhalation risk values covering all major tobacco-related diseases. Many literature data are available on Int. J. Environ. Res. Public Health 2011, 8                 
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the  presence  of  chemical  components  in  cigarette  smoke,  often  with  concentration  ranges  and 
occasionally with information on the toxic potency of these components. However, to the best of our 
knowledge,  an  exhaustive  list  of  smoke  components  was  not  available at the start of the project. 
Therefore, a database has been generated by reviewing recent literature on smoke components. From 
our database components with known potential health risks for cancer or other endpoints (primarily 
cardiovascular and respiratory effects) have been selected as an initial list for regulatory purposes.  
2. Experimental Section 
2.1. Database Composition 
To screen for smoke components, peer-reviewed literature dating back to 1990 has been searched 
using PubMed and Scopus. The following search query was used: (―cigarette smoke‖ OR ―tobacco 
smoke‖  OR  ―mainstream  smoke‖)  AND  (toxin  OR  analyte*  OR  constituent*  OR  deliveries  OR 
composition* OR component* OR compound* OR ―gas phase‖ OR particulate OR toxin* OR ―smoke 
chemistry‖ OR emission*). 
In addition, all issues of Recent Advances in Tobacco Science have been checked, as well as all 
issues of the journal Beitraege zur Tabakforschung International dating back to 1990. Existing lists 
such as the Hoffmann list, the WHO TobReg list [13], the Rodgman & Green list [14], and the Fowles 
and Dybing list [15] have also been used. Finally, several textbooks on smoke composition have been 
consulted [10,16-22].  
Information retrieved from these data sources were entered in an Excel database. The database 
contains detailed information on each chemical compound and its levels in mainstream tobacco smoke, 
if  available.  Available  human  inhalation  risk  values  (cancer  and  non-cancer  risk,  safety  factors 
included) from the International Toxicity Estimates for Risk Assessment (ITER) database have also 
been  incorporated.  ITER  is  an  Internet  database  of  chronic  human  health  risk  values  and  cancer 
classifications for over 542 chemicals of environmental concern obtained from several independent 
organizations worldwide (http://www.tera.org/ITER). This database is updated on a regular basis and 
contains risk values from the Agency for Toxic Substances and Disease Registry of the Centers for 
Disease  Control  of  the  United  States  (ATSDR),  Health  Canada  (HC),  International  Agency  for 
Research  on  Cancer  (IARC),  NSF  International,  Rijksinstituut  voor  Volksgezondheid  en  Milieu 
(RIVM; National Institute of Public Health and the Environment, the Netherlands), and the United 
States Environmental Protection Agency (U.S. EPA). When more than one of these institutes  has 
published a risk value, the lowest value was selected for our database. In addition, risk values from the 
Californian  Environmental  Protection  Agency  (Cal  EPA)  as  listed  in  the  articles  of  Fowles  and  
Dybing [23] and Rodgman and Green [14], were included. One NATA (U.S. EPA National-scale Air 
Toxics  Assessment)  and  two  ORNL  (U.S.  EPA  Department  of  Energy,  Office  of  Environmental 
Management) values listed in Rodgman and Green were also included.  Int. J. Environ. Res. Public Health 2011, 8                 
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2.2. Derivation of Smoke Components Threshold of Toxicological Concern 
From the available inhalation risk values for tobacco smoke components thresholds of toxicological 
concern (TTC) have been established. Two TTCs were derived, one from all risk values including 
carcinogens, and one for endpoints other than carcinogenicity. To derive the threshold of toxicological 
concern, the 5th percentile benchmark dose was taken from the plot of the cumulative probability 
versus the inhalation risk values. It should be noted that risk values from different agencies were used, 
which may affect the accuracy of our TTC. Agencies often base their risk assessment on different 
toxicological data, and apply different safety factors. 
3. Results and Discussion  
3.1. Database and List of Hazardous Smoke Components 
Our literature search resulted in a database of 2,256 different smoke components. For 542 of these 
components, yields per cigarette in mainstream smoke were also reported in literature. For the other 
compounds, only the presence in smoke was mentioned, but the amount not specified. To assess the 
human health risk of a specific smoke component, data on its smoke yield and inhalation risk value are 
required. For 98 components, risk assessment authorities have established a human inhalation risk 
value for cancer and/or another endpoint: 60 cancer and 48 non-cancer inhalation risk values have 
been found. These 98 components were selected for our list of hazardous smoke components, as their 
potential hazard  contribution can  be  assessed. Table 1 lists  these  components,  together with  their 
inhalation risk values and the institute that published this value. Searching the recent publication on 
tobacco  and  tobacco  smoke  components  by  Rodgman  and  Perfetti  [24],  containing  references  to 
around 5,300 smoke components, may result in hazardous smoke components not yet on our list. 
Emission  levels  are  known  from  literature  for  all  98  components  except  for  five  that  had  been 
measured but not quantified in smoke. Exposure to the components on this list forms a potential health 
risk to develop cancer and/or other diseases, primarily cardiovascular and respiratory illnesses.  
Our list  of  hazardous  smoke  components  includes  all  nine  components  reported  in mainstream 
cigarette smoke that are known human carcinogens (IARC Group I carcinogens), as well as all nine 
components  that  are  probably  carcinogenic  to  humans  (IARC  Group  2A  carcinogens)  [25,26].  
In addition, it contains 34 of the 48 components that are possibly carcinogenic to humans (IARC 
Group 2B carcinogens) [27].  
The WHO Study Group on Tobacco Product Regulation (TobReg) recently published an expert 
advice  on  smoke  component  regulation  (based  on  research  by  a  joint  WHO  and  IARC  working  
group) [13,28]. A list of 43 priority toxicants was composed from three smoke component emission 
level datasets which were all based on the Hoffmann list. All components of this TobReg initial group 
of  priority  toxicants  are  present  on  our  list,  with  the  exception  of  catechol,  crotonaldehyde, 
hydroquinone,  and  NNK.  Those  components  are  not  on  the  current  list  as  no  human  inhalation  
risk values were found. Catechol has been classified by IARC as possibly carcinogenic to humans  
(Group 2B); hydroquinone and crotonaldehyde have been classified by IARC as not classifiable as to 
its carcinogenicity to humans (Group 3).  Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. List of hazardous tobacco smoke components with their cancer and non-cancer inhalation risk values. 
Smoke component 
Cancer risk value 
1  
(mg m
−3)
  Institute 
Non-cancer risk value 
2 
(mg m
−3)
  Endpoint  Institute 
1,1,1-Trichloro-2,2-bis(4-chlorophenyl)ethane 
(DDT )  1.0E-04  U.S. EPA       
1,1-Dimethylhydrazine  2.0E-06  ORNL       
1,3-Butadiene  3E-04  U.S. EPA  2E-03  reproduction  U.S. EPA 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TEQ)  2.6E-04  Cal EPA        
2-Amino-3-methyl-9H-pyrido[2,3-b]indole 
(MeAaC)  2.9E-05  Cal EPA        
2-Amino-3-methylimidazo[4,5-b]quinoline (IQ)  2.5E-05  Cal EPA        
2-Amino-6-methyl[1,2-a:3',2"-d]imidazole  
(GLu-P-1)   7.1E-06  Cal EPA        
2-Aminodipyrido[1,2-a:3',2"-d]imidazole  
(GLu-P-2)   2.5E-05  Cal EPA        
2-Aminonaphthalene  2.0E-05  Cal EPA        
2-Nitropropane    Cal EPA   0.02  liver, focal vacuolization and nodules  U.S. EPA 
2-Toluidine  2.0E-04  Cal EPA        
3-Amino-1,4-dimethyl-5H-pyrido 
[4,3-b]indole (Trp-P-1)  1.4E-06  Cal EPA        
3-Amino-1-methyl-5H-pyrido[4,3-b]-indole 
(Trp-P-2)   1.1E-05  Cal EPA        
4-Aminobiphenyl   1.7E-06  Cal EPA       
5-Methylchrysene  9.1E-06  Cal EPA        
7H-Dibenzo(c,g)carbazole  9.1E-06  Cal EPA        
2-Amino-9H-pyrido[2,3-b]indole (AaC)  8.8E-05  Cal EPA        
Acetaldehyde  4.5E-03  U.S. EPA  9.0E-03  nasal olfactory epithelial lesions  U.S. EPA 
Acetamide  5.0E-04  Cal EPA       
Acetone      30  neurological effects  ATSDR 
Acetonitrile       0.06  mortality  U.S. EPA Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. Cont. 
Smoke component 
Cancer risk value 1  
(mg m
−3)  Institute 
Non-cancer risk value 2 
(mg m
−3)  Endpoint  Institute 
Acrolein      2.0E-05  nasal lesions  U.S. EPA 
Acrylamide  8E-3         
Acrylic acid      1.0E-03  nasal olfactory epithelium degeneration  U.S. EPA 
Acrylonitrile  1.5E-04  U.S. EPA  2.0E-03  respiratory effects  U.S. EPA 
Ammonia      0.1  respiratory effects  U.S. EPA 
Aniline 
B2—probable human 
carcinogen  U.S. EPA  1E-3  immune-related  U.S. EPA 
Arsenic  2.3E-06  U.S. EPA       
Benz[a]anthracene  9.1E-05  Cal EPA       
Benzene  1.3E-03  U.S. EPA  9.8E-03  decreased lymphocyte count  ATSDR 
Benzo[a]pyrene  9.1E-06  Cal EPA       
Benzo[j]fluoranthene  9.1E-05  Cal EPA       
Beryllium  4.2E-06         
Cadmium  5.6E-06  U.S. EPA       
Carbazole  1.8E-03  NATA       
Carbon disulfide      0.1  effects on CNS  HC 
Carbon monoxide      10  cardiotoxic  Cal EPA  
Chloroform,  4.3E-04  U.S. EPA  0.1  liver changes  ATSDR 
Chromium VI   8.3E-07  U.S. EPA  1.0E-04  lower respiratory effects  U.S. EPA 
Chrysene  9.1E-04  Cal EPA       
Cobalt      5.0E-04  respiratory functions  RIVM 
Copper      1.0E-03  lung and immune system effects  RIVM 
Di(2-ethylhexyl) phthalate  4.2E-03  Cal EPA        
Dibenzo[a,i]pyrene  9.1E-07  Cal EPA        
Dibenzo[a,h]acridine  9.1E-05  Cal EPA        
Dibenzo[a,h]anthracene  8.3E-06  Cal EPA        
Dibenzo[a,j]acridine  9.1E-05  Cal EPA        Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. Cont. 
Smoke component 
Cancer risk value 1  
(mg m
−3) 
Institute  Non-cancer risk value 2 
(mg m
−3)  Endpoint  Institute 
Dibenzo[a,h]pyrene  9.1E-07  Cal EPA        
Dibenzo[a,l)pyrene   9.1E-07  Cal EPA        
Dibenzo[a,e]pyrene  9.1E-06  Cal EPA        
Dibenzo[c,g]carbazole  9.1E-06  Cal EPA        
Dimethylformamide 
    3.0E-02 
digestive disturbances; minimal hepatic 
changes  U.S. EPA 
Ethyl carbamate  3.5E-05  Cal EPA       
Ethylbenzene      0.77  liver and kidney effects  RIVM 
Ethylene oxide  1.1E-04  Cal EPA        
Ethylenethiourea  7.7E-04  Cal EPA        
Formaldehyde  7.7E-04  U.S. EPA  1.0E-02  nasal irritation  ATSDR 
Hexane      0.7  neurotoxicity  U.S. EPA 
Hydrazine  2.0E-06  U.S. EPA  5E-3  fatty liver changes  ATSDR 
Hydrogen cyanide      3.0E-03  CNS and thyroid effects  U.S. EPA 
Hydrogen sulfide       2E-3  nasal lesions  U.S. EPA 
Indeno(1,2,3-c,d)pyrene  9.1E-05  Cal EPA       
Isopropylbenzene      0.4  increased kidney, adrenal gland weights  U.S. EPA 
Lead  8.3E-04  Cal EPA  1.5E-3  not applicable  U.S. EPA 
Manganese      5.0E-05  neurobehavioral  U.S. EPA 
m-Cresol      0.17  CNS  RIVM 
Mercury      2.0E-04  nervous system  U.S. EPA 
Methyl chloride      0.09  cerebellar lesions  U.S. EPA 
Methyl ethyl ketone      5  developmental toxicity  U.S. EPA 
Naphtalene      3E-3  nasal effects  U.S. EPA 
N-nitrosodi-n-butylamine (NBUA)  6.3E-06  U.S. EPA       
N-nitrosodimethylamine (NDMA)  7.1E-07  U.S. EPA       
Nickel 
    9.0E-05 
chronic active inflammation and  
lung fibrosis  ATSDR 
Nitrogen dioxide      1.0E-01  not applicable  U.S. EPA Int. J. Environ. Res. Public Health 2011, 8                 
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Table 1. Cont. 
Smoke component 
Cancer risk value 1  
(mg m
−3)  Institute 
Non-cancer risk value 2 
(mg m
−3)  Endpoint  Institute 
N-nitrosodiethanolamine  1.3E-05  Cal EPA       
N-nitrosodiethylamine  2.3E-07  U.S. EPA       
N-nitrosoethylmethylamine   1.6E-06  Cal EPA        
N-Nitrosonornicotine (NNN)  2.5E-05  Cal EPA        
N-Nitroso-N-propylamine  5.0E-06  Cal EPA        
N-nitrosopiperidine   3.7E-06  Cal EPA        
N-nitrosopyrrolidine  1.6E-05  U.S. EPA       
n-Propylbenzene      0.4  increased organ weight  U.S. EPA 
o-Cresol 
C- possible human 
carcinogen 
U.S. EPA  0.17  decreased body weight, neurotoxicity 
RIVM 
 
p-, m-Xylene      0.1  respiratory, neurological, developmental  U.S. EPA 
p-Benzoquinone  
C- possible human 
carcinogen  U.S. EPA  0.17  CNS  RIVM 
p-Cresol 
C- possible human 
carcinogen  U.S. EPA  0.17  CNS  RIVM 
Phenol 
    0.02 
liver enzymes, lungs, kidneys, and 
cardiovascular system  RIVM 
Polonium-210  925.9  ORNL
3        
Propionaldehyde      8.0E-03  atrophy of olfactory epithelium   U.S. EPA 
Propylene oxide  2.7E-03  U.S. EPA       
Pyridine      0.12  odour threshold  RIVM 
Selenium      8E-4  respiratory effects  Cal EPA 
Styrene      0.092  body weight changes and neurotoxic effects  HC 
Toluene      0.3  colour vision impairment  ATSDR 
Trichloroethylene  82  HC  0.2  liver, kidney, CNS effects  RIVM 
Triethylamine      7.0E-03  n.a.  U.S. EPA 
Vinyl acetate      0.2  nasal lesions  U.S. EPA 
Vinyl chloride  1.1E-03  U.S. EPA       
1 Cancer inhalation risk values provide an excess lifetime exposure risk, in this case the human lung cancer risk at a 1 in 100,000 (E-5) level.  
2 Noncancer inhalation risk values indicate levels and exposure times at which no adverse effect is expected; here values for continuous lifetime exposure are listed.  
3 Unit risk in risk/pCi = 1.08E-08. Int. J. Environ. Res. Public Health 2011, 8                 
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Considering this classification, these components probably do not form the highest carcinogenic 
risk of all components in tobacco smoke. Only NNK, that has been classified as Group 1 since 2007 
(before 2B) would be worthwhile to include after determining a risk value. In the TobReg article, no  
non-cancer  hazard  indices  are  mentioned.  Thus,  our  shortlist  of  98  potentially  hazardous  smoke 
components  includes  all  important smoke  components  from these  previous lists.  Compared to the 
Hoffmann  list,  our  list  includes  many  new  components  including  acetone,  acetonitrile,  cadmium, 
methyl chloride, methyl ethyl ketone, propionaldehyde and toluene.  
3.2. Threshold of Toxicological Concern in Smoke Risk Assessment 
As human health inhalation risk values have been found for only 98 of the 2,256 smoke components, 
the potential hazard contribution can only be assessed for these components when using classical risk 
assessment criteria. An alternative approach is to look at smoke components with an emission level 
below the threshold of toxicological concern (TTC). The TTC refers to a human exposure threshold 
below  which  there  would  be  no  appreciable  risk  to  human  health,  despite  the  absence  of  
chemical-specific toxicity data [29,30]. When a chemical would be present at concentrations below 
this level, it can be exempted from further hazard consideration. The TTC is usually a cut-off value 
based  on  a  set  of  experimental  data,  e.g.,  the  5th  percentile  value  of  the  distribution  of  a  set  of  
no-observed  effect levels (NOEL). TTCs can be defined for several endpoints, the most sensitive  
being mutagenicity. 
The  inhalation  exposure-based  TTC  for  tobacco  smoke  components  was  established  at  
0.0009 µ g m
−3 for all risk values including those for carcinogens (5th percentile benchmark dose), and 
0.06  µ g  m
−3  for  risk  values  excluding  carcinogenic  components.  These  concentrations  can  be 
remodeled to daily doses of respectively 0.0018 and 1.2 µ g day
−1 by assuming a default breathing rate 
of 20 m
3 day
−1. It should be noted that the compounds for which we found human inhalation risk 
values have been assessed because they are known or suspected toxicants (selection bias). This means 
that, had our entire dataset been tested for toxicity, the TTC would have turned out higher. Below, our 
TTC for non-carcinogenic effects is compared to inhalation exposure based TTCs found in literature.  
Escher  et  al.  report  an  inhalation  TTC  for  non-carcinogenic  endpoints  of  4–180  µ g  day
−1 
(depending on the Cramer class of the component) based on repeated dose toxicity studies from the 
REPDOSE database [31,32]. No observed effect concentrations (NOECs) have been normalized to 
daily exposure, and converted to daily doses using a default breathing rate of 20 m
3 day
−1 and a safety 
factor of 25; organophosphates and compounds with a genotoxic structural alerts were excluded. Their 
value is comparable in magnitude to our TTC for non-carcinogenic components. 
Carthew et al. derived a TTC for inhalation exposure to aerosol ingredients in consumer products 
from an inhalation toxicology database of over 100 rodent studies [33]. Using a safety factor of 25, 
they derived a TTC of 300 µ g day
−1 for systemic effects and a TTC of 1,000 µ g day
−1 for local effects. 
Genotoxic carcinogens and in vivo mutagens have been excluded from their analysis, as well as heavy 
metals, dioxins, polychlorinated biphenyls, organophosphates and polymers. This may explain why 
their TTC values are higher (250 and 830 times) than our TTC for non-carcinogenic components. Int. J. Environ. Res. Public Health 2011, 8                 
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Based  on  analysis  of  toxicological  data  for  hundreds  of  carcinogenic  and  noncarcinogenic 
substances, the FDA derived a human TTC for oral exposure of 1.5 µg  day
−1. Drew and Frangos 
remodeled this value to an air guideline TTC of 0.03 µ g m
−3 assuming default breathing factors, and 
100% absorption in the lungs [34]. Next, they compared this inhalation TTC to air guideline values 
established by reputable authorities. Their air guideline database was comprised of organics only and 
did not include carcinogens, sensory irritants, metals, particulates, and dioxins. For the chronic air 
guideline values established by risk assessment authorities, there are three guideline values lower than 
the TTC and 280 at or above the TTC. For 3,274 acute air guideline values established by various 
authorities and from occupational exposure limits, only one value was below the TTC. Thus, the FDA 
human TTC for oral exposure, 1.5 µg  day
−1, seems to result in a reasonable estimation for inhalatory 
exposure to non-carcinogens, as well. Our TTC for non-carcinogens (1.2 µ g day
−1) is almost equal to 
the FDA value.  
Thus, the non-carcinogens TTC we derived from inhalation risk values for smoke components is 
comparable to previously reported inhalation TTCs for non-carcinogenic effects. For 542 components 
in  our  database,  a  concentration  range  in  smoke  is  known.  As  a  smoker  consumes  on  average  
20 cigarettes per day, these levels have to be multiplied by 20 to estimate a smoker‘s daily exposure. 
For 81 of these components, the concentration in  smoke is lower than the TTC for all endpoints 
including carcinogenicity. If the TTC approach would also be valid for the complex mixture of tobacco 
smoke, this means that for 15% (81/542) of the components with known concentration in smoke, there 
would  be  no  appreciable  risk  for  any  disease  including  cancer.  As  a  first  approximation,  these 
components could be exempted from further hazard consideration, especially if one considers that as 
many as 461 (542 – 81) smoke components with known concentration levels are present at levels 
above  the  TTC  and  would  therefore  have  a  higher  priority  for  hazard  characterization  anyway. 
However, one has to take into account that the TTC approach has been developed for exposure to 
single  components  or  simple  mixtures.  The  complex  tobacco  smoke  mixture,  on  the  other  hand, 
contains  more  than  5,000  components.  Any  effects  of  these  components  could  be  antagonistic, 
independent,  additive,  or  even  synergistic,  depending  on  the  specific  mechanisms  of  toxicity.  
Price et al. modeled an independent and an additive approach for some simple model mixtures [35]. 
Further research could study this problem for the much more complex tobacco smoke mixture. 
For 172 of these components, the concentration in smoke is lower than the TTC for endpoints other 
than carcinogenicity. Thus, for 32% (172/542) of the components with known concentration in smoke, 
there would be no appreciable risk at diseases other than cancer. These components could be exempted 
from further hazard consideration if they are proven non-carcinogens and/or have no structural alerts 
for carcinogenicity.  
In conclusion, we have derived two inhalation TTCs, one for all risks, including carcinogenicity, 
and  one  for  endpoints  other  than  carcinogenicity,  the  latter  being  well  comparable  to  previously 
reported inhalation TTCs for non-carcinogenic effects. Only a small part of the smoke components 
with known yields have emission levels below these TTCs.  Int. J. Environ. Res. Public Health 2011, 8                 
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3.3. How to Use the Initial List for Tobacco Product Regulation?  
Our list of 98 smoke components provides a scientific basis for the progressive reduction in the 
level of toxic chemicals in tobacco emissions. The WHO TobReg expert advice on smoke component 
regulation proposed lowering of toxicants levels per mg nicotine in cigarette smoke [13,28]. First, the 
levels for selected smoke components would need to be established and second, sale or import of 
cigarette  brands  that  have  yields  above  these  levels  could  be  prohibited.  The  Centre  for  Disease 
Control in Atlanta already implemented a similar approach by monitoring the levels of three categories 
of chemicals (tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, and volatile organic 
compounds) in tobacco smoke and setting a target to reduce the unit-based sales-weighted average 
levels of each category by 10% [36].  
As  the  risk  for  tobacco  smoke-related  diseases  appears  to  be  dose-dependent,  reducing  the 
concentration  of  the  most  important  toxicants  in  smoke  may  lower  the  risks  related  to  tobacco  
smoking  [37].  This  harm  reduction  approach  is  interesting  because  in  many  countries  smoking 
prevalence  seems  to  stabilize  after  an  initial  steep  decline  secured  by  various  policy  measures. 
However, the effect on mortality and morbidity of lowering (classes of) toxins in cigarette smoke has 
not  been  clarified  yet,  one  of  the  reasons  being  the  relatively  long  lag  time  for  developing  
tobacco-related  diseases.  Additional  studies  are  required  to  assess  individual-  or  population-level 
reductions  in  exposure  or  in  adverse  health  effects.  For  instance,  the  consumption  of  modified 
cigarettes cannot be linked easily to a reduction in disease risk or even to significant reductions in 
carcinogen exposure biomarkers [37]. Second, past experiences with the introduction of low-yield 
tobacco  products  showed  unforeseen  effects  that  counteracted  any  harm  reduction  effects.  The 
resulting products did not lead to reduced exposure as consumers adapted their smoking behavior such 
as frequency and intensity of use to inhale sufficient nicotine to satisfy their craving and addiction 
[38,39].  On  the  other  hand,  consumers  did  perceive  these  products  to  be  less  hazardous  due  to 
marketing health claims, such as ‗light‘ and ‗mild‘ [40-42]. As these circumstances may lead to a 
negative health impact, TobReg also advised to report toxicant levels normalized for nicotine level and 
to prevent marketing of products with reduced toxicant levels as such. Such normalization may lead to 
less  focus  on  the  quantity  of  smoke  generated  per  cigarette,  and  on  TNCO  values  as  misleading 
measures of human exposure and risk. On the other hand, toxicant emission levels for cigarettes with 
different nicotine emission levels can be better compared. According to TobReg, normalization may 
shift  the  interpretation  of  the  measurement  towards  product  characterization  of  smoke  toxicity 
generated under standardized conditions.  
In addition to the potential health effect of a smoke component, other criteria are important in 
selecting  components  for  regulation  (e.g.,  [13,28]).  First,  the  component  must  have  substantial 
variability in its yield across brands on the market to allow for banning of part of the products. Second 
and somewhat related, the variation across brands should be substantially greater than the variation in 
repeat measurement for the component for a single brand. Otherwise, large numbers of measurements 
would be required for each component in order to tighten the estimation of the mean value, and the 
cost of testing would increase proportionally. Third, compounds from different chemical classes need 
to  be  included.  Analyses  of  variation  in  brands  of  13  mainstream  smoke  emissions  suggests  the 
occurrence of risk swapping (in which one specific exposure is reduced within a group at the cost of Int. J. Environ. Res. Public Health 2011, 8                 
 
 
624 
another's exposure increasing) and risk shifting (in which a specific exposure is reduced within a group 
at the cost of that exposure‘s increasing within another group) [43]. For instance, when polycyclic 
aromatic hydrocarbons are reduced by enhancing nitrate content in tobacco, more tobacco specific 
nitrosamines are generated in smoke. Therefore, it is warranted that marker components of all relevant 
chemical classes are included on a list for regulatory purposes.  
A final consideration to select smoke components for regulation is the availability of technology, or 
other approaches, that can reduce the level of specific smoke components, as setting limits on these 
toxicants then becomes feasible and therefore of higher priority. Some smoke component emission 
levels may be lowered by adapting agricultural practices, plant characteristics, tobacco blending, and 
cigarette design (for example additives, filters, papers) [44]. For instance, parameters which influence 
heavy metal concentration in tobacco include growing conditions (e.g., soil type and pH), agricultural 
practices  (e.g.,  use  of  metal-containing  pesticides  and  fertilizers),  genotype,  stalk  position,  and 
processing of tobacco leaves [45]. Another example is the formation of carbonyls in tobacco smoke by 
the pyrolysis of tobacco components, including celluloses and sugars. Sugar levels in tobacco can be 
reduced  by  using  different  curing  methods,  and  regulating  the  amount  that  is  added  in  the 
manufacturing process  [46]. A third example is the yield of many organics in smoke that can be 
influenced by the type of filter, e.g., charcoal filters remove up to 70% of benzene from cigarette 
smoke [11]. 
The current shortlist is solely based on toxicity data from publicly available databases. Thus, other 
toxic smoke components may be present in our database, but do not appear on the shortlist due to lack 
of an inhalation risk value. Apart from that, additives and their resulting smoke components may also 
increase tobacco-related harm by making cigarettes more palatable, attractive, or even addictive to 
consumers.  From  a  regulatory  point  of  view,  identifying  smoke  components  that  influence 
addictiveness of tobacco products is also essential. In addition, smoke components that increase the 
attractiveness of a tobacco product by affecting e.g., taste, smell and other sensory attributes also need 
to be cautiously regulated as these may entice more individuals to start or to continue smoking.  
Some of the components in Table 1 or in our database are not only toxic, but also increase the 
addictiveness or the attractiveness of a cigarette. For instance, aldehydes such as acetaldehyde may 
play a role in cigarette addiction as do the components harman and norharman present in our database 
[47].  Other  components  may  affect  the  taste  of  tobacco  smoke  to  a  high  extent  and  thus  its 
attractiveness. One example is 5-hydroxymethylfurfural, a characteristic taste component of Maillard 
reactions [48]. Unfortunately no sufficient evidence is available on smoke components‘ addictiveness 
or  attractiveness  or  on  appropriate  methods  to  acquire  these  data  [49].  Therefore,  future  research 
should also focus on these two aspects of tobacco smoking.  
In conclusion, our initial list of 98 smoke components can be used for regulatory purposes like the 
progressive reduction in the level of toxic chemicals in tobacco emissions. A further selection from 
these 98 components can be made based on criteria such as the variability of the toxicants across 
brands, the potential for the toxicant to be lowered, the need to include components from different 
chemical classes, and any attractiveness- or addictiveness-enhancing effects of components.  Int. J. Environ. Res. Public Health 2011, 8                 
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4. Conclusions  
Here we provide a list of 98 hazardous smoke components (Table 1) which is based on an extensive 
literature  search  for  known  smoke  components  and  their  human  health  inhalatory  risk.  This  list 
provides a scientific basis for the progressive reduction in the level of toxic chemicals in tobacco 
product emissions, through periodic setting of standards. It is advised to replace the Hoffmann list by 
the current list of hazardous smoke components. As components with potential cardiovascular and 
respiratory effects have also been included, the three major smoke-related causes of death are all 
covered by the list. Future updating of this list can be carried out as needed. Based on the inhalatory 
risks, we also derived two thresholds of toxicological concern (TTCs),  one for all risks including 
carcinogenicity,  and  one  for  endpoints  other  than  carcinogenicity,  which  is  well  comparable  to 
previously reported inhalation TTCs for non-carcinogenic effects. Only a small part of the smoke 
components with known yields has emission levels below these TTCs. 
Many  components  on  our  list  (e.g.,  styrene,  acetamide,  and  methyl  chloride)  have  not  been 
systematically  studied  in  benchmark  experiments  comprising  a  variety  of  brands  available  on  the 
market, and should therefore be monitored. When these data have been generated, the variability of the 
toxicants  across  brands,  and  the  potential  for  the  toxicant  to  be  lowered,  can  be  evaluated.  It  is 
therefore recommended that the list of hazardous smoke components be monitored in several brands 
using different smoking regimes. For many components validated methods are already available from 
e.g., International Organisation for Standardization (ISO) or Health Canada. For other components, 
such methods need to be developed or modified from other applications. In the framework of FCTC, 
harmonized  and  validated  standards  will  be  developed  for  measuring  NNK,  NNN,  acetaldehyde, 
acrolein, benzene, benzo(a)pyrene, 1,3-butadiene, carbon monoxide, and formaldehyde. 
Once the list of components has been further studied and monitored, and the results have been 
evaluated,  a  further selection  from the  shortlist  can be  made  for  regulatory purposes. Here,  other 
criteria  such  as  the  variability  of  the  toxicants  across  brands,  the  potential  for  the  toxicant  to  be 
lowered, the need to include components from different chemical classes, and any attractiveness- or 
addictiveness-enhancing effects of components can be incorporated. Routine collection and analysis of 
selected smoke components will accelerate advancement in tobacco control.  
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